Biogen Idec Gains Phase II MS, Cancer Biologics Through PDL Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
The agreement gives Biogen rights to Protein Design Labs' daclizumab, volociximab and fontolizumab.
You may also be interested in...
Ophthotech Will Take Biogen/PDL Drug Volociximab Into The Clinic For AMD
Alpha 5 beta 1 integrin antagonist will move into the clinic “shortly,” CEO Patel tells “The Pink Sheet” DAILY.
Ophthotech Will Take Biogen/PDL Drug Volociximab Into The Clinic For AMD
Alpha 5 beta 1 integrin antagonist will move into the clinic “shortly,” CEO Patel tells “The Pink Sheet” DAILY.
Biogen Idec/PDL BioPharma Plan To Study Daclizumab As Monotherapy For MS
Phase II monotherapy trial for the monoclonal antibody will initiate in the second half of 2007, PDL tells “The Pink Sheet” DAILY.